Top

Published in:

01-10-2021 | Colchicine | Original Article

Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial

Authors: Arash Gholoobi, Vahid Reza Askari, Hossein Naghedinia, Mostafa Ahmadi, Vida Vakili, Vafa Baradaran Rahimi

Published in: Inflammopharmacology | Issue 5/2021

Abstract

Myocardial infarction without ST-segment elevation (NSTEMI) is considered an inflammatory disorder associated with a high mortality rate worldwide. High-sensitivity C-reactive protein (hs-CRP) is an important inflammatory marker for NSTEMI and related to cardiovascular events. Colchicine, as a potent anti-inflammatory drug, is frequently prescribed for the treatment of gout and pericarditis. The present study aimed to evaluate the effects of colchicine, as an anti-inflammatory drug, on hs-CRP levels in NSTEMI patients. We performed a randomised, double-blind, placebo-controlled trial involving 150 NSTEMI patients referred to Imam Reza and Ghaem Hospitals affiliated to Mashhad University of Medical Sciences. The patients were randomised to receive colchicine or placebo along with optimal medications for 30 days. The hs-CRP was measured at the admission and end of the study. Our results revealed that, in both colchicine and placebo groups, hs-CRP levels were significantly mitigated in NSTEMI patients compared to baseline (P < 0.001). However, the decreasing properties of colchicine on hs-CRP levels were remarkably stronger than placebo following the 30 days of treatment (P < 0.001). Nevertheless, neither colchicine nor placebo treatment could achieve hs-CRP levels lower than 2 mg/L. There were no significant differences between the effects of colchicine on the hs-CRP decrease in diabetic and non-diabetic, male and female, and normal and preserved LVEF NSTEMI patients. It can be concluded that colchicine may prevent the disease progression and succedent cardiovascular events in NSTEMI patients by attenuating the inflammation.

Akodad M, Lattuca B, Nagot N, Georgescu V, Buisson M, Cristol JP, Leclercq F, Macia JC, Gervasoni R, Cung TT, Cade S, Cransac F, Labour J, Dupuy AM, Roubille F (2017) COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch Cardiovasc Dis 110(6–7):395–402. https://doi.org/10.1016/j.acvd.2016.10.004CrossRefPubMed

Akodad M, Sicard P, Fauconnier J, Roubille F (2020) Colchicine and myocardial infarction: a review. Arch Cardiovasc Dis 113(10):652–659. https://doi.org/10.1016/j.acvd.2020.04.007CrossRefPubMed

Askari VR, Baradaran Rahimi V, Tabatabaee SA, Shafiee-Nick R (2019) Combination of Imipramine, a sphingomyelinase inhibitor, and β-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol 77:105923. https://doi.org/10.1016/j.intimp.2019.105923CrossRefPubMed

Baradaran Rahimi V, Rakhshandeh H, Raucci F, Buono B, Shirazinia R, Samzadeh Kermani A, Maione F, Mascolo N, Askari VR (2019) Anti-inflammatory and anti-oxidant activity of portulaca oleracea extract on LPS-induced rat lung injury. Molecules. https://doi.org/10.3390/molecules24010139CrossRefPubMedPubMedCentral

Basit H, Malik A, Huecker MR (2021) Non ST segment elevation myocardial infarction. StatPearls, Treasure Island

Cohen M, Visveswaran G (2020) Defining and managing patients with non-ST-elevation myocardial infarction: sorting through type 1 vs other types. Clin Cardiol 43(3):242–250. https://doi.org/10.1002/clc.23308CrossRefPubMedPubMedCentral

Crea F, Liuzzo G (2016) Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine. Eur Heart J 37(30):2414–2416. https://doi.org/10.1093/eurheartj/ehw207CrossRefPubMed

Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL (2018) Colchicine: an ancient drug with novel applications. Br J Dermatol 178(2):350–356. https://doi.org/10.1111/bjd.15896CrossRefPubMedPubMedCentral

Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM (2020) Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol 76(14):1660–1670. https://doi.org/10.1016/j.jacc.2020.08.011CrossRefPubMed

Fiolet ATL, Silvis MJM, Opstal TSJ, Bax WA, van der Horst FAL, Mosterd A, de Kleijn D, Cornel JH (2020) Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS ONE 15(8):e0237665–e0237665. https://doi.org/10.1371/journal.pone.0237665CrossRefPubMedPubMedCentral

Harrington DH, Stueben F, Lenahan CM (2019) ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: medical and surgical interventions. Crit Care Nurs Clin North Am 31(1):49–64. https://doi.org/10.1016/j.cnc.2018.10.002CrossRefPubMed

Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, Hillis GS (2019) The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 215:62–69. https://doi.org/10.1016/j.ahj.2019.06.003CrossRefPubMed

Leung YY, Yao Hui LL, Kraus VB (2015) Colchicine-update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 45(3):341–350. https://doi.org/10.1016/j.semarthrit.2015.06.013CrossRefPubMedPubMedCentral

Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, Hasan AA, Amar S (2018) Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol 72(17):2071–2081. https://doi.org/10.1016/j.jacc.2018.08.1043CrossRefPubMedPubMedCentral

Neumann JT, Goßling A, Sörensen NA, Blankenberg S, Magnussen C, Westermann D (2020) Temporal trends in incidence and outcome of acute coronary syndrome. Clin Res Cardiol 109(9):1186–1192. https://doi.org/10.1007/s00392-020-01612-1CrossRefPubMed

Nidorf M, Thompson PL (2007) Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 99(6):805–807. https://doi.org/10.1016/j.amjcard.2006.10.039CrossRefPubMed

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61(4):404–410. https://doi.org/10.1016/j.jacc.2012.10.027CrossRefPubMed

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383(19):1838–1847. https://doi.org/10.1056/NEJMoa2021372CrossRefPubMed

Rahimi VB, Askari VR, Mousavi SH (2018) Ellagic acid reveals promising anti-aging effects against d-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: a mechanistic study. Biomed Pharmacother 108:1712–1724. https://doi.org/10.1016/j.biopha.2018.10.024CrossRefPubMed

Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352(1):20–28. https://doi.org/10.1056/NEJMoa042378CrossRefPubMed

Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ (2019) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380(8):752–762. https://doi.org/10.1056/NEJMoa1809798CrossRefPubMed

Smit M, Coetzee AR, Lochner A (2020) The pathophysiology of myocardial ischemia and perioperative myocardial infarction. J Cardiothorac Vasc Anesth 34(9):2501–2512. https://doi.org/10.1053/j.jvca.2019.10.005CrossRefPubMed

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381(26):2497–2505. https://doi.org/10.1056/NEJMoa1912388CrossRefPubMed

Teo YN, Teo YH, Syn NL, Goh MW, Yoong CSY, Lee CH, Chan MY, Chai P, Yeo TC, Sia CH (2021) Effects of colchicine on cardiovascular outcomes in patients with coronary artery disease: a systematic review and one-stage and two-stage meta-analysis of randomized-controlled trials. High Blood Press Cardiovasc Prev. https://doi.org/10.1007/s40292-021-00460-yCrossRefPubMed

Tong DC, Wilson AM, Layland J (2016) Colchicine in cardiovascular disease: an ancient drug with modern tricks. Heart 102(13):995–1002CrossRef

Vanhaverbeke M, Veltman D, Pattyn N, De Crem N, Gillijns H, Cornelissen V, Janssens S, Sinnaeve PR (2018) C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up. Clin Cardiol 41(9):1201–1206. https://doi.org/10.1002/clc.23017CrossRefPubMedPubMedCentral

Title: Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial
Authors: Arash Gholoobi
Vahid Reza Askari
Hossein Naghedinia
Mostafa Ahmadi
Vida Vakili
Vafa Baradaran Rahimi
Publication date: 01-10-2021
Publisher: Springer International Publishing
Keywords: Colchicine
Myocardial Infarction
Acute Coronary Syndrome
Published in: Inflammopharmacology / Issue 5/2021
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-021-00865-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer’s disease: flavonoids and phenols

Effects of nitro-butoxyl- and butyl-esters of non-steroidal anti-inflammatory drugs compared with parent compounds on the contractility of digital arterial smooth muscle from the fallow deer (Dama dama)

A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug

Acteoside isolated from Colebrookea oppositifolia attenuates I/R brain injury in Wistar rats via modulation of HIF-1α, NF-κB, and VEGF pathways

A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study

Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis